EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lisinopril Tablet Quality Evaluation: A Pharmacopeial Compliance Study

Faizah Bakre, Adekunle Ayodele, Iyanu Oluwafemi Awotuya, Katherine Olufolabo, Fagbohun Babasola, Olabanji Daodu, James Olaitan, Saka Kasim

Advances in Clinical Pharmacology and Therapeutics · 2025

DOI: 10.63623/hcfv6209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical Pharmacology and Therapeutics, 2025. Verfasst von Faizah Bakre und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The quality of pharmaceutical products is critical in ensuring therapeutic efficacy and patient safety, particularly in managing chronic conditions like hypertension.

Objectives

This study assessed the quality of five different brands of Lisinopril tablets using pharmacopeial standards to evaluate their compliance with required specifications.

Methods

Five brands were analyzed through High-Performance Liquid Chromatography (HPLC), weight uniformity, hardness, friability, and disintegration tests. HPLC was employed for content assay, while mechanical and release characteristics were assessed using pharmacopoeial protocols.

Results

HPLC analysis showed that all brands contained Lisinopril within the USP acceptable range of 90–110% of the labeled claim. The weight uniformity test confirmed compliance, with all brands falling within the ±7.5% limit. Hardness values varied significantly: brands PR, FI, and ED passed with mean values of 8.5 KgF, 8.3 KgF, and 5.0 KgF respectively, while brands LF and RL failed with values of 3.7 KgF and 3.3 KgF. Friability percentages ranged from 0.105% (FI) to 0.842% (LF), well below the 1% limit. Disintegration times also varied, with all brands meeting the pharmacopeial standard of

Zitieren

APA

Bakre, F., Ayodele, A., Awotuya, I. O., Olufolabo, K., Babasola, F., Daodu, O., Olaitan, J., & Kasim, S. (2025). Lisinopril Tablet Quality Evaluation: A Pharmacopeial Compliance Study. Advances in Clinical Pharmacology and Therapeutics. https://doi.org/10.63623/hcfv6209

Vancouver

Bakre F, Ayodele A, Awotuya IO, Olufolabo K, Babasola F, Daodu O, et al. Lisinopril Tablet Quality Evaluation: A Pharmacopeial Compliance Study. Advances in Clinical Pharmacology and Therapeutics. 2025. doi:10.63623/hcfv6209

BibTeX
@article{Bakre2025,
  author = {Bakre, Faizah and Ayodele, Adekunle and Awotuya, Iyanu Oluwafemi and Olufolabo, Katherine and Babasola, Fagbohun and Daodu, Olabanji and Olaitan, James and Kasim, Saka},
  title = {Lisinopril Tablet Quality Evaluation: A Pharmacopeial Compliance Study},
  journal = {Advances in Clinical Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.63623/hcfv6209}
}
Kostenlos starten →